Obesity is associated with type 2 diabetes, hypertension and hyperlipidaemia. Modest weight loss has been shown to have a beneficial effect on these cardiovascular risk factors and to improve risk factor clustering. Recent lifestyle intervention studies also suggest that modest weight loss can help to prevent two of the most common conditions associated with obesity: hypertension and type 2 diabetes. The practical problem is how to translate results from these studies into daily practice. In the studies, only a limited number of individuals maintained substantial weight loss over the follow up period. New approaches are needed to achieve and maintain weight loss.
Introduction
Epidemiological studies have shown that obesity is associated with increased cardiovascular risk. 1 The excess cardiovascular risk associated with increased body fat is accounted for, at least in part, by its association with type 2 diabetes, hypertension and dyslipidaemia. 2 Whether or not obesity should be considered as an independent cardiovascular risk factor is still a matter of debate, but the rising worldwide prevalence and severity of obesity demands initiatives to treat and prevent the cardiovascular disease burden associated with this disease.
It is now well established that moderate weight loss has a beneficial effect on the cardiovascular risk factors associated with obesity. 3 A 5 -10% weight reduction has been associated with an improvement in fasting glycaemia, glycosylated haemoglobin (HBA 1c ), systolic and diastolic blood pressure and plasma lipid profile.
The UK Prospective Diabetes Study showed a significant correlation between the amount of weight loss during 3 months' dieting after the diagnosis of type 2 diabetes and the decrease in fasting plasma glucose over the same time period. 4 Virtually all aspects of peripheral glucose uptake have shown improvement with weight loss. Moreover, moderate weight reduction has been associated with a reduction in the use of glucose lowering medication and an improvement in the co-morbidities associated with type 2 diabetes. 5, 6 Finally, data on the follow-up of overweight individuals with diabetes enrolled in the American Cancer Society's Cancer Prevention Study suggest that voluntary modest weight loss is associated with a 25% reduction in total mortality in type 2 diabetic patients. 7 The beneficial effects of a moderate weight reduction on hypertension and serum lipids have also been well established. The meta-analysis by MacMahon et al showed an average decrease in systolic and diastolic blood pressure of 0.68 and 0.34 mmHg respectively with each kg of weight loss. 8 According to a meta-analysis by Dattilo, a weight loss of 1 kg decreases serum cholesterol by 2.28 mg=dl, LDL cholesterol by 0.91 mg=dl, and triglycerides by 1.54 mg=dl. 9 Recent data suggest that these beneficial effects apply not only to the absolute plasma lipid levels but also to some important qualitative features of lipoproteins. Vasankari et al reported that a 1 y weight loss intervention program was associated with reduction in the plasma concentration of oxidized-LDL particles. 10 The reduction of this most atherogenic of LDL-particles was proportional to the amount of weight lost. A weight loss of around 10% of the initial body weight was associated with a 33% reduction in the ratio of oxidized LDL to total LDL.
Obesity is not only associated with each of the major cardiovascular risk factors, but is also a determinant of clustering of cardiovascular risk factors. Follow-up of the Framingham cohort demonstrated a dose-dependent effect of body mass index on this risk factor clustering. 11 This is an important concept as the hazard of developing coronary disease in persons with any particular risk factor has been noted to increase in proportion to the concomitant burden of other risk factors. Clusters of three or more risk factors have been associated with a three and six times greater risk of coronary heart disease in men and women, respectively. A modest weight reduction has been shown to be beneficial in reducing the clustering of major cardiovascular risk factors. Individuals in the Framingham cohort who lost at least 2.25 kg over 16 y, had a 40 -50% reduction in their total risk factor score, a measure of clustering. In contrast, those who gained as little as 2.25 kg had a 20 -40% increase, depending on gender, in that same score.
In summary, therefore, there is compelling data showing that a modest weight lost is beneficial in the treatment of type 2 diabetes, hypertension and dyslypidaemia. However, it should be stressed that once these determinants of the obesity associated cardiovascular risk are present the benefits of weight loss may be somewhat limited. The altered metabolic state may not be restored to normality, and those patients with more advanced conditions may not respond equally to weight loss interventions as those in the earlier phases of the disease.
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Weight loss and diabetes prevention
In addition to the benefits of weight loss in disease treatment, recent intervention studies have shown that a weight reduction of 5 -10% is very effective in preventing the appearance of type 2 diabetes and hypertension in overweight individuals.
The US Diabetes Prevention Program Research Group recently reported data on a large randomized clinical trial of type 2 diabetes prevention.
14 More than 3200 overweight adults of diverse ethnic backgrounds with impaired glucose tolerance were included in the study. Participants were allocated to placebo, metformin, or to an 'intensive' lifestyle intervention group. This last group received diet, exercise and behaviour modification, and aimed for a 7% reduction in body weight. Those in the lifestyle intervention group had lost around 7 kg after 6 months; although some of the weight was later regained, weight loss was still around 4 kg at the end of follow-up (Figure 1 ). In the placebo group, in whom there was no significant change in body weight, the cumulative incidence of diabetes was around 11 new cases=100 patients=y. Lifestyle intervention was highly effective in preventing -or at least delaying -the appearance of type 2 diabetes. Compared with the placebo group, there was a 58% reduction (P < 0.001) in the incidence of diabetes in the lifestyle intervention group (Figure 2) . Importantly, this applied across the range of baseline BMI values (overweight, grade 1 obesity or grade 2 obesity).
The smaller Finnish Diabetes Prevention Study (FDPS) also showed that modest weight reduction can reduce the incidence of type 2 diabetes. 15 Like the DPP, the study included a control group and a lifestyle intervention group aiming at modest weight reduction and increased physical activity. Even though the mean weight reduction in the intervention group was only 4 kg in the first year (corresponding to 5% of initial body weight), individuals in this group showed a 58% lower cumulative incidence of diabetes compared to subjects in the control group (P < 0.001; Figure 3 ). Weight loss in the FDPS was not only beneficial in reducing type 2 diabetes, it also positively affected some other cardiovascular risk factors. As Table 1 shows, weight loss was associated with a significant reduction in the waist circumference and also with an improvement in plasma triglycerides and in systolic and diastolic blood pressure, emphasising the pleiotropic effects of a modest weight loss. 
Weight loss and hypertension prevention
The US Trials of Hypertension Prevention, Phase II (TOHP-II), evaluated the impact of weight loss on the incidence of hypertension. It included 1191 individuals who were overweight (110 -165% of ideal body weight) and had a 'borderline' blood pressure (systolic blood pressure < 140 mmHg, diastolic blood pressure 83 -89 mmHg). 16 Individuals were allocated to a usual care group or to a weight-loss intervention group aiming at a 4.5 kg weight reduction during the first 6 months of the trial and to maintain their weight loss for the remainder of the trial.
As in the diabetes prevention studies, the intervention included dietary change, physical activity and behaviour modification. Individuals in the control group had a slight weight increase throughout the study period. In the intervention group, mean weight change from baseline was À4.4 kg at 6 months, À2.0 kg at 18 months and À0.2 kg at 36 months. Although weight loss was not maintained in the intervention group, mean body weight in this group was always significantly lower than in the control group.
At all time points in follow-up (6, 18 and 36 months), the cumulative incidence of hypertension was significantly lower in the intervention group than in the control group (Figure 4) . Importantly, there was a dose -response relationship between the degree of weight loss and the magnitude of blood pressure reduction ( Figure 5 ). Participants who lost 4.5 kg or more at 6 months and maintained that weight loss over 36 months showed a 65% reduction in the risk of being classified as hypertensive at the end of follow up compared with those who did not lose weight. 16 The challenge of maintaining weight loss Each of the above-mentioned studies has provided convincing data on the benefits of a modest weight reduction. However, the proportion of patients that benefit from the lifestyle interventions is limited by the difficulty in maintaining weight loss. In the three prevention studies described, the proportion of individuals that achieved weight loss goals was low and appeared to decline over time. In FDPS, after 1 y of follow-up, 43% of patients had achieved the goal of a 5% weight reduction. In DPP, 38% of the patients achieved the 7% weight loss goal after 2.8 y of follow-up, this figure being lower than the 50% of patients that had achieved the weight loss goal at 6 months' followup. In TOHP II, only 13% of patients in the total cohort achieved and maintained the weight loss goal of 4.5 kg after 3 y of follow-up. Given the proven beneficial effects of a modest weight reduction, this would clearly point to the need for the development of better methods to achieve and maintain weight loss.
Conclusion
Modest weight loss -5 -10% of initial body weight -has been shown to have a beneficial effect on cardiovascular risk factors associated with obesity and to improve risk factor clustering. Recent lifestyle intervention studies also suggest that modest weight loss can help to prevent or delay the appearance of type 2 diabetes and hypertension. However, the success rate of lifestyle intervention on weight loss is limited and appears to diminish over time. Despite intensive lifestyle intervention programmes offered in major trials, only a limited number of individuals succeeded in maintaining substantial weight loss over follow up. New approaches are needed to achieve and maintain weight loss so that the Benefits of weight loss J Vidal
